Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.75 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | HPGD | P15428 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.75 |
| ▸ | NPC1 | O15118 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | RAB9A | P51151 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | CA12 | O43570 | 6/20 | 0.67 |
| ▸ | CA1 | P00915 | 6/20 | 0.67 |
| ▸ | CA2 | P00918 | 6/20 | 0.67 |
| ▸ | CA9 | Q16790 | 6/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20090510 | 0.91 | ALDH1A1 (0.62) | ALDH1A1LMNAHPGDKDM4ENPC1 | |
| SCHEMBL3699464 | 0.90 | MAPK1 (0.71) | ALDH1A1LMNAHPGDKDM4ENPC1 | |
| SCHEMBL12302132 | 0.84 | ALDH1A1 (0.90) | ALDH1A1LMNAHPGDKDM4ENPC1 | |
| SCHEMBL19454404 | 0.83 | ALDH1A1 (0.71) | ALDH1A1LMNAHPGDKDM4ENPC1 | |
| SCHEMBL19580347 | 0.83 | ALDH1A1 (0.71) | ALDH1A1LMNAHPGDKDM4ENPC1 | |
| SCHEMBL24762147 | 0.83 | ALDH1A1 (0.75) | ALDH1A1LMNAHPGDKDM4ENPC1 | |
| SCHEMBL3126117 | 0.83 | ALDH1A1 (0.75) | ALDH1A1LMNAHPGDKDM4ENPC1 | |
| SCHEMBL386724 | 0.83 | ALDH1A1 (0.75) | ALDH1A1LMNAHPGDKDM4ENPC1 | |
| SCHEMBL31014207 | 0.83 | ALDH1A1 (0.75) | ALDH1A1LMNAHPGDKDM4ENPC1 | |
| SCHEMBL29967391 | 0.83 | ALDH1A1 (0.75) | ALDH1A1LMNAHPGDKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024243485-A1 | CDK2 INHIBITORS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | NUVATION BIO INC. (US) | 2021-11-16 | — | — | US | disclosed |
| CN-112334451-A | Heterocyclic compounds as kinase inhibitors | 诺维逊生物股份有限公司 | 2021-02-05 | — | — | CN | disclosed |
| EP-3752491-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Nuvation Bio Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| WO-2019161224-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | GiraFpharma LLC (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-08-15 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-6855719-B1 | Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine derivatives | ASTRAZENECA AB (SE) | 2005-02-15 | — | — | US | disclosed |
| US-20040198757-A1 | 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors | ASTRAZENECA AB (SE) | 2004-10-07 | — | — | US | disclosed |
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-06-10 | — | — | US | disclosed |
| US-20040106574-A1 | 2-Arylamino-pyrimidines for the treatment of gsk3-related disorders | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | US | disclosed |
| EP-1406876-A1 | 2-ANILINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | Astrazeneca AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| US-20030216406-A1 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| EP-1353922-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | Cancer Research Technology Limited (GB) | 2003-10-22 | — | — | EP | disclosed |
| EP-1214318-B1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002096887-A1 | 2-ANILINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002059125-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | CDK6, CDK4, CDK9 | ALDH1A1 2534/4885LMNA 2478/4885HPGD 584/4885 |
| US-20040106574-A1 | 2-Arylamino-pyrimidines for the treatment of gsk3-related disorders | GSK3A, GSK3B, CKS2 | ALDH1A1 3696/4885LMNA 1157/4885HPGD 2161/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | ALDH1A1 4333/4885LMNA 3015/4885HPGD 4082/4885 |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | ALDH1A1 2992/4885LMNA 3004/4885HPGD 556/4885 |
| US-20040198757-A1 | 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors | CCNT1, CCNI, CDK2 | ALDH1A1 1217/4885LMNA 863/4885HPGD 1342/4885 |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | ALDH1A1 2992/4885LMNA 3004/4885HPGD 556/4885 |
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CCNA1, CDKL1, CCNK | ALDH1A1 2396/4885LMNA 345/4885HPGD 2212/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | ALDH1A1 4184/4885LMNA 3115/4885HPGD 4156/4885 |
| US-20030216406-A1 | Pyrimidine derivatives | TYMP, TYMS, CCNT1 | ALDH1A1 482/4885LMNA 2359/4885HPGD 920/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | ALDH1A1 4184/4885LMNA 3115/4885HPGD 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.